Your browser doesn't support javascript.
loading
Endothelial function after pancreas transplantation-A single-center observational study.
Nordheim, Espen; Dahle, Dag Olav; Halden, Thea; Birkeland, Kåre I; Åsberg, Anders; Hartmann, Anders; Horneland, Rune; Jenssen, Trond Geir.
  • Nordheim E; Department of Transplantation Medicine, Section of Nephrology, Oslo University Hospital, Rikshospitalet, Oslo, Norway.
  • Dahle DO; Faculty of Medicine, University of Oslo, Oslo, Norway.
  • Halden T; Department of Transplantation Medicine, Section of Nephrology, Oslo University Hospital, Rikshospitalet, Oslo, Norway.
  • Birkeland KI; Department of Transplantation Medicine, Section of Nephrology, Oslo University Hospital, Rikshospitalet, Oslo, Norway.
  • Åsberg A; Department of Transplantation Medicine, Section of Nephrology, Oslo University Hospital, Rikshospitalet, Oslo, Norway.
  • Hartmann A; Faculty of Medicine, University of Oslo, Oslo, Norway.
  • Horneland R; Department of Transplantation Medicine, Section of Nephrology, Oslo University Hospital, Rikshospitalet, Oslo, Norway.
  • Jenssen TG; Department of Pharmacy, University of Oslo, Oslo, Norway.
Clin Transplant ; 34(3): e13815, 2020 03.
Article en En | MEDLINE | ID: mdl-32027399
BACKGROUND: Patients with diabetes mellitus treated with successful pancreas transplantation (PTX) normalize hyperglycemia, but are exposed to immunosuppressive drugs that may impair endothelial function. This study aimed to evaluate endothelial function in single PTX recipients. METHODS: Flow-mediated dilatation (FMD) in the brachial artery was measured by ultrasound 8 weeks after transplantation in single PTX (n = 27) and compared with healthy controls (n = 58), simultaneous pancreas and kidney recipients (n = 9), and kidney transplant recipients with (n = 41) and without (n = 95) diabetes mellitus. Adjustments for age, gender, blood pressure, and body mass index were included in a linear regression model. Changes in FMD from before to 1 year after transplantation were assessed in a subgroup of PTX recipients (n = 9). RESULTS: Flow-mediated dilatation% in PTX recipients was not inferior to healthy controls (8.7 ± 3.6 vs 7.7 ± 3.3, P = .06) and simultaneous pancreas and kidney recipients (6.7 ± 4.5, P = .24) in an adjusted model, and superior to kidney recipients with and without diabetes (3.0 ± 3.0 and 4.8 ± 3.3, respectively, both P < .005). FMD% improved significantly from eight weeks to one year after PTX, mean 7.9 ± 4.2% vs 11.8 ± 4.8% (N = 9; P = .03). CONCLUSION: Flow-mediated dilatation is well preserved in patients undergoing pancreas transplantation and is not impaired when immunosuppressive drugs are introduced.
Asunto(s)
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Trasplante de Riñón / Trasplante de Páncreas / Diabetes Mellitus Tipo 1 Tipo de estudio: Diagnostic_studies / Observational_studies Límite: Humans Idioma: En Año: 2020 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Trasplante de Riñón / Trasplante de Páncreas / Diabetes Mellitus Tipo 1 Tipo de estudio: Diagnostic_studies / Observational_studies Límite: Humans Idioma: En Año: 2020 Tipo del documento: Article